Second Genome secures $42.6m funding to expand microbiome discovery platform
The round was co-led by Pfizer Venture Investments and Roche Venture Fund, and brings the combined total investment in the company to $59 million. The round also included
Arna Pharma and Slate Run Pharmaceuticals have completed a joint venture (JV) to form a speciality pharmaceutical company in the US focusing on branded products, 505(b)(2) medicines, and specialised generics.
The alliance will evaluate the potential for combining Astex’s guadecitabine (SGI-110) small molecule DNA hypomethylating agent with Genentech’s atezolizumab investigational anti-PD-L1 monoclonal antibody. The safety and pharmacology of